Is it safe?
Can ABT take a bad year?
Abbott Laboratories carries $26.8B of net debt at 2.91× EBITDA: a load its earnings can carry.
$26.8B
Net debt · as at Q1 2026 · between two and four years of EBITDA, normal for a stable business
- Net debt / EBITDA
- 2.91×
Net debt / EBITDA · 0.76× a year ago · the load is going up
- Altman Z-score
- 4.54
Altman Z-score · safe zone, above 3
- Interest cover
- 14.4×
Interest cover · operating profit covers the interest bill several times over
Details›
- Total debtQ1 2026
- $34.0B
- Cash and short-term investments
- $7.29B
- Net debt
- $26.8B
- EBITDA, trailing twelve months
- $9.18B
- Operating profit, trailing twelve months
- $7.71B
- Debt / equity
- 0.65×
- Total debt / EBITDA
- 3.71×
- Annualised volatilitytwo years of daily moves
- 24%
- Worst drawdown on file
- −40%
- Below its 52-week high
- −15%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Medical Devices
Ranks #16 of 35 by Smart Score